Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 12:13 PM ET


Company Overview of Watson Laboratories, Inc.

Company Overview

Watson Laboratories, Inc. manufactures pharmaceutical drugs. The company was incorporated in 1992 and is based in Corona, California. Watson Laboratories, Inc. operates as a subsidiary of Allergan plc.

132 Business Center Drive

Corona, CA 92880-1724

United States

Founded in 1992



Key Executives for Watson Laboratories, Inc.

Watson Laboratories, Inc. does not have any Key Executives recorded.

Watson Laboratories, Inc. Key Developments

Celgene Settles REVLIMID Patent Litigation with Natco Pharma Ltd., Arrow International Limited and Watson Laboratories, Inc

Celgene Corporation announced the settlement of litigation with Natco Pharma Ltd., Arrow International Limited, and Arrow’s parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide). As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as described below. In settlement of all outstanding claims in the litigation, Celgene will permit entry of generic lenalidomide before the April 2027 expiration of Celgene’s last-to-expire patent listed in the Orange Book for REVLIMID®. Celgene has agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States beginning on January 31, 2026. In addition, Natco will receive a volume-limited license to sell generic lenalidomide in the United States commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total lenalidomide capsules dispensed in the United States during the first full year of entry. The volume limitation is expected to increase gradually each 12 months until March of 2025, and is not expected to exceed one-third of the total lenalidomide capsules dispensed in the U.S. in the final year of the volume-limited license under this agreement. Natco’s ability to market lenalidomide in the U.S. will be contingent on its obtaining approval of an Abbreviated New Drug Application.

Cipher Pharmaceuticals Announces Outcome of Markman Hearing in Patent Infringement Suit for Absorica®

Cipher Pharmaceuticals Inc. announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a "Markman hearing") for the patent infringement suit by Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., Galephar Pharmaceutical Research Inc., and Cipher against Watson Laboratories, Inc. ("Watson", now Actavis plc) related to Watson's Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). The purpose of a Markman hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit.  No ultimate determination of infringement or validity of the patents has been determined at this point.

Federal Trade Commission Approves Final Order Preserving Future Competition in Generic Injectable Tuberculosis Drug Market

Federal Trade Commission has approved a final order settling charges that Akorn, Inc.'s acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would have likely been anticompetitive. Under the order, first announced in August 2014, Akorn is required to divest its Abbreviated New Drug Application for generic injectable rifampin - which is currently pending before the Food and Drug Administration - to Watson Laboratories, Inc. According to the FTC's complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin. There are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC alleged that if Akorn had consummated its acquisition of VersaPharm as originally proposed, the combined company would have been likely to delay or cancel the introduction of Akorn's generic injectable rifampin.

Similar Private Companies By Industry

Company Name Region
ThyoGen Pharmaceuticals Inc. United States
Vetix, Inc. United States
Theregen, Inc. United States
Roex Inc. United States
Proprius Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Watson Laboratories, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at